Effect of N_Acetylcysteine on Liver Functions in Donors in Living Liver Transplantation

Ain Shams University

Status and phase: Completed; Phase 2; Phase 1

Conditions: Liver Transplant; Complications

Treatments: Drug: Placebo; Drug: N-Acetylecysteine

Study type: Interventional

Funder types: Other

Identifiers

NCT03634566

R 10/2018

Details and patient eligibility

About

our practice for the past 10 years we have noticed a transitional impairment of liver function (elevated liver enzymes, total and direct bilirubin, and elevated serum lactate levels) following donors' liver resection. Several drugs have been investigation on liver regeneration , proven benefit of N-Acetylcysteine (NAC) on rats with steatohpatitis

Enrollment: 50 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ASA I or II donors
• healthy adult

Exclusion criteria

• kidney, liver disease
• any contraindications for organ donation

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 2 patient groups, including a placebo group

NAC group

Active Comparator group

Description:

Group NC received NAC 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days

Treatment:

Drug: N-Acetylecysteine

Control group

Placebo Comparator group

Description:

Group C (Control group) will receive ringer acetate continuous infusion at same rate for 2 days.

Treatment:

Drug: Placebo